Your browser doesn't support javascript.
loading
The COVID-19 vaccine patent: a right without rationale.
Althabhawi, Nabeel Mahdi; Kashef Al-Ghetaa, Ali Adil.
Afiliação
  • Althabhawi NM; Law, Universiti Kebangsaan Malaysia, Bangi, Selangor, Malaysia althabhawi@ukm.edu.my.
  • Kashef Al-Ghetaa AA; Department of Law, Al-Mustaqbal University College, Hillah, Iraq.
Med Humanit ; 49(1): 128-133, 2023 Mar.
Article em En | MEDLINE | ID: mdl-35523578
Since the approval of COVID-19 vaccines, international efforts have intensified on vaccination schemes perceived as the only light at the end of the tunnel. Governments are working tirelessly to scale up the number of vaccinated people, just as vaccine manufacturers are stretching their facilities to meet the increasing demand for doses. The international community is trying to help the poorest countries in the world by improving vaccine supplies and removing obstacles. In this regard, India and South Africa have applied to World Trade Organisation to waive vaccine-related intellectual property rights. The proposal has sparked off academic debates as to its merit. This article addresses the waiver controversy. Following a critical review of both dimensions of the controversy, the article concentrates on the extent to which the waiver application contradicts the theoretical justification of the patent system. It concludes that the concerns raised over the conflict between the waiver proposal and the patent right philosophy are indefensible.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas / COVID-19 Limite: Humans País como assunto: Asia Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas / COVID-19 Limite: Humans País como assunto: Asia Idioma: En Ano de publicação: 2023 Tipo de documento: Article